CMS Not Ready To Declare Genomic Testing Reasonable And Necessary
This article was originally published in The Gray Sheet
Executive Summary
Officials from CMS remain optimistic about the long-term potential for genomic testing, but have not yet found enough clinical evidence in favor of Medicare coverage
You may also be interested in...
CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It
Medicare will only cover genetic testing for individual response to the blood-thinner warfarin in the context of controlled clinical studies, effective immediately, CMS said Aug. 3
Family History May Be Key To Wider Adoption Of Genetic Screening
Before the market for genetic screening tests can take off, health care providers must do a better job of collecting their patients' family history, according to experts speaking May 6 at CMS headquarters in Baltimore
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”